11/17 Taiwan BIO Weekly
2026-11-17| Taiwan BIO Weekly |
| Taiwan's Bora Pharmaceuticals Q3 EPS Hits Record NT$4.79 as Specialty Brand Drugs Climb to 47% of Sales 14 November, 2026 Bora Pharmaceuticals (TW: 6472) reported its 2026 third-quarter results, with consolidated revenue of NT$6.453 billion (approximately $196.3 million), up 9.6% quarter-on-quarter to a record quarterly high. Net profit after tax came in at NT$654 million (approximately US$19.9 million), with earnings per share of NT$4.79, up 9.9% quarter-on-quarter. More... |
| OBI Pharma Signs Collaboration and License Agreement with Novartis Press release 13 November, 2026 OBI Pharma, Inc. (TW: 4174) announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. More... |
| AP Biosciences to Sign MOU with External Partner for Co-Development of Bispecific ADCs 12 November, 2026 AP Biosciences (TW: 6945) plans to expand its bispecific antibody-drug conjugate (bsADC) pipeline through a collaboration with an unnamed external company. Its board has approved the proposed partnership and authorized the general manager to negotiate and sign a formal agreement. The collaboration will combine AP Biosciences' proprietary antibody library and bispecific antibody engineering capabilities to develop innovative cancer therapies based on next-generation mechanisms of action. More... (in Chinese) |
| Enimmune Targets Key ASEAN Markets with Singapore Submission of Enterovirus Vaccine 12 November, 2026 Enimmune (TW: 6564), a subsidiary of Adimmune (TW: 4142), has submitted a new drug application (NDA) for its Enterovirus 71 vaccine, EnVAX-A71, to Singapore's Health Sciences Authority (HSA), marking an important step in its expansion into Southeast Asia. With no enterovirus vaccines currently available in Singapore, the submission could help address an important public health need while providing a potential model for Taiwan to work with ASEAN countries to establish a regional enterovirus protection network. More... (in Chinese) |
| BIONET Therapeutics Wins Indonesian Approval for Two Exosome Products 12 November, 2026 BIONET Therapeutics (TW: 7808), an emerging-market listed subsidiary of BIONET (TW: 1784), announced that its two exosome products, BIOCAKE and BIOCAKE Lite, have received product approval from Indonesia's Food and Drug Authority (BPOM), marking another step in its expansion into Southeast Asia. Targeting Indonesia's 290 million-strong consumer market, the company is leveraging its regenerative medicine R&D and manufacturing capabilities to establish distribution across 13 cities and more than 2,000 medical aesthetic clinics, expanding its regional presence and tapping into the growing skin longevity market. More... (in Chinese) |
| TaiMed Biologics' HIV Combination Therapy Clinical Results Published in Leading Medical Journal 11 November, 2026 TaiMed Biologics (TW: 4147) announced that results from its US Phase Ib/IIa clinical trial of TMB-365/TMB-380, a proprietary long-acting monoclonal antibody combination therapy for HIV, have been published in The Lancet HIV. The study evaluated the safety, pharmacokinetics, and antiviral activity of TMB-365, a CD4-directed monoclonal antibody, combined with TMB-380, a long-acting broadly neutralizing antibody targeting the CD4-binding site of HIV-1. More... (in Chinese) |
| Advagene Biopharma Completes Phase II Dosing for Asthma Drug, Results Expected in Q1 2027 11 November, 2026 Advagene Biopharma (TW: 6709) announced that its drug candidate AD17002, developed for moderate to severe eosinophilic asthma, has successfully completed dosing for all participants in its Phase II clinical trial. The company expects to unblind and analyze the trial data in Q1 2027, followed by the release of final clinical results. More... (in Chinese) |
| Sunmax Brings Together Asia-Pacific Medical Experts for Deusaderm APAC Summit 2026, Celebrating 25 Years of Collagen Innovation Press release 10 November, 2026 Sunmax Biotechnology Co., Ltd. (TW: 4728) celebrated its 25th anniversary by bringing together medical aesthetics experts from across Asia-Pacific at Deusaderm APAC Summit 2026, held Nov. 8-10 at METT Singapore. The event convened approximately 140 aesthetic physicians, clinic leaders and partners from Singapore, Malaysia, Thailand, the Philippines, Japan, mainland China and Taiwan. More... |
| Roche Pharma Taiwan General Manager Diana Liu and the Future of Healthcare Innovation 9 November, 2026 When Diana Liu took over as General Manager of Roche Pharma Taiwan in May 2025, she brought nearly two decades of experience in the pharmaceutical industry, including three and a half years leading Roche's operations in Hong Kong and Macau. More... |
| EirGenix's October Revenue Hits YoY Record High 9 November, 2026 EirGenix (TW: 6589) has reported record-high October 2026 revenue of NT$272 million, up 287.88% year-over-year, driven by growth in its CDMO business and international licensing income from biosimilars EG12014 and EG1206A. Cumulative revenue for the first ten months reached NT$1.385 billion, an increase of 94.7%. With EG1206A targeting European and U.S. market launches in 2027 and 2028, respectively, alongside expanding commercial CDMO orders, EirGenix anticipates significant improvements in its operating scale and profitability in the second half of 2027. More... (in Chinese) |
| Lumosa Grants Global Distribution Rights for Painkiller LT1001, Shifts Focus to Stroke Drug LT3001, Drug Pipeline 9 November, 2026 Lumosa Therapeutics (TW: 6535) announced on 9 November the launch of its "Lumosa 2.0" transformation strategy. The board approved granting the global distribution rights for its long-acting pain relief drug LT1001 to Taiwan's AMED, aiming to expand the product's market reach through external commercialization channels. Lumosa will redirect its core resources toward the development of its stroke drug LT3001 and a pipeline of cutting-edge advanced therapies. More... (in Chinese) |
| Handa Pharmaceuticals Speeds Up Omcazio US Launch Through Sales and Licensing 9 November, 2026 Handa Pharmaceuticals (TW: 6620) has begun commercial-scale production, drug serialization, and pre-launch preparations for HND-039 Omcazio in the US, while evaluating both direct sales and licensing partnerships. The 505(b)(2) drug has received final US FDA approval, shifting the company's focus from regulatory review to distribution, shipment arrangements, and finalizing its commercialization strategy ahead of its US market launch. More... (in Chinese) |
| PharmaEssentia's October Revenue More Than Doubles YoY, Reaching Record High 5 November, 2026 PharmaEssentia (TW: 6446) announced on November 5th that its October revenue reached a record NT$2.84 billion, up 7.6% month-on-month and 102.0% year-on-year, driven by steady sales growth of its flagship drug Ropeg in the polycythemia vera (PV) market. The launch of Ropeg's prefilled injection pen in the US in July, further boosting adoption and contributing to double-digit sales growth in the US market. More... (in Chinese) |
| HanchorBio Signs MOU with Kaohsiung Hospital for Collaboration on Novel Cancer Therapies 5 November, 2026 HanchorBio (TW: 7827) announced on November 5th that it has signed an MOU with Kaohsiung Medical University Chung-Ho Memorial Hospital to explore potential clinical research collaboration. The partnership aims to combine HanchorBio's innovative drug development expertise with the hospital's clinical expertise in gastrointestinal cancers to evaluate clinical trial opportunities, subject to regulatory and institutional review board approvals. More... (in Chinese) |
| ========================================= |
| Please note that Taiwan BIO is not responsible for the accuracy of third-party news stories covered in this newsletter. |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2027 (27-31 July, 2027) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |
